Darbepoetin alfa was given to 4038 subjects with type 2 DM and CKD with the eGFR range of 20-60 ml/min/1.73 m2) in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) to accomplish the target Hb (13 g/dl) or to placebo, with darbepoetin being given when the Hb was < 9 g/dl [22]. This evidence concerns the gene GSTM1 and chronic kidney disease.